Spyre Therapeutics, Inc.

SYRE

NASDAQ

Healthcare

Biotechnology

Waltham, MA, US73 employeesspyre.com

$47.67

-1.23(-2.52%)

Mkt Cap $2.9B

$11.80

$50.44

52-Week Range

At a Glance

AI-generated

Spyre Therapeutics, Inc.

Revenue breakdown: Development Fee And Royalty (100%).

8-K

Spyre Therapeutics, Inc. issued a press release via Exhibit 99.1 regarding its financial results. The filing is furnished under Item 2.02 and includes Item 9.01 for financial statements and exhibits.

$2.9B

Market Cap

$16M

Revenue

-$27M

Net Income

Employees73

Fundamentals

How The Business Makes Money

Revenue by Segment

Development Fee And Royalty100%($886.0K)

Activity

What Changed Recently

Financial Results

Feb 18, 2026

, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “E

Regulation FD

Jan 11, 2026

of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes o

Peer Companies

Company	Price	Change	Market Cap	P/E
CLDXCelldex Therapeutics, Inc...	$31.00	-0.85%	$2.1B	-8.2
IMNMImmunome, Inc.	$21.86	-2.63%	$1.9B	-8.5
ZYMEZymeworks Inc.	$25.77	-0.66%	$1.9B	-22.3
PHVSPharvaris N.V.	$28.50	-3.21%	$1.9B	-8.3
NTLAIntellia Therapeutics, In...	$13.13	-1.09%	$1.6B	-3.4
ARDXArdelyx, Inc.	$5.92	-3.03%	$1.5B	-21.0
MAZEMaze Therapeutics, Inc.	$28.82	-0.77%	$1.4B	-17.8
WVEWave Life Sciences Ltd.	$7.25	+6.08%	$1.4B	-10.2

Analyst View

Company Profile

CIK0001636282

ISINUS00773J2024

CUSIP00773J202

Phone617 651 5940

Address221 Crescent Street, Waltham, MA, 02453, US

SEC EDGAR